Ofir Wolach

3.1k total citations
107 papers, 1.5k citations indexed

About

Ofir Wolach is a scholar working on Hematology, Public Health, Environmental and Occupational Health and Oncology. According to data from OpenAlex, Ofir Wolach has authored 107 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 66 papers in Hematology, 25 papers in Public Health, Environmental and Occupational Health and 24 papers in Oncology. Recurrent topics in Ofir Wolach's work include Acute Myeloid Leukemia Research (53 papers), Acute Lymphoblastic Leukemia research (24 papers) and Hematopoietic Stem Cell Transplantation (21 papers). Ofir Wolach is often cited by papers focused on Acute Myeloid Leukemia Research (53 papers), Acute Lymphoblastic Leukemia research (24 papers) and Hematopoietic Stem Cell Transplantation (21 papers). Ofir Wolach collaborates with scholars based in Israel, United States and Netherlands. Ofir Wolach's co-authors include Richard M. Stone, Meir Lahav, Pia Raanani, Ron Ram, Osnat Bairey, Ofer Shpilberg, Moshe Yeshurun, Anat Gafter‐Gvili, Baruch Wolach and Liat Vidal and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Ofir Wolach

100 papers receiving 1.5k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Ofir Wolach Israel 21 761 461 390 366 290 107 1.5k
Masatsugu Tanaka Japan 24 1.1k 1.4× 349 0.8× 263 0.7× 345 0.9× 476 1.6× 196 1.9k
Lori Anderson United States 14 821 1.1× 422 0.9× 276 0.7× 260 0.7× 378 1.3× 25 1.9k
Krzysztof Kałwak Poland 21 738 1.0× 179 0.4× 240 0.6× 282 0.8× 376 1.3× 149 1.5k
Odile Fenneteau France 20 731 1.0× 310 0.7× 302 0.8× 303 0.8× 302 1.0× 79 1.8k
Kimikazu Matsumoto Japan 20 567 0.7× 270 0.6× 154 0.4× 370 1.0× 237 0.8× 122 1.3k
Emmanuelle Tavernier France 18 840 1.1× 326 0.7× 194 0.5× 629 1.7× 330 1.1× 73 1.4k
Friedrich Stölzel Germany 22 1.0k 1.3× 539 1.2× 553 1.4× 241 0.7× 409 1.4× 92 1.9k
Hsiu‐Hao Chang Taiwan 23 317 0.4× 420 0.9× 228 0.6× 232 0.6× 248 0.9× 101 1.4k
Celalettin Üstün United States 29 1.6k 2.1× 866 1.9× 498 1.3× 369 1.0× 664 2.3× 147 3.0k
J Treleaven United Kingdom 28 1.1k 1.5× 397 0.9× 291 0.7× 334 0.9× 515 1.8× 71 2.0k

Countries citing papers authored by Ofir Wolach

Since Specialization
Citations

This map shows the geographic impact of Ofir Wolach's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ofir Wolach with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ofir Wolach more than expected).

Fields of papers citing papers by Ofir Wolach

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ofir Wolach. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ofir Wolach. The network helps show where Ofir Wolach may publish in the future.

Co-authorship network of co-authors of Ofir Wolach

This figure shows the co-authorship network connecting the top 25 collaborators of Ofir Wolach. A scholar is included among the top collaborators of Ofir Wolach based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ofir Wolach. Ofir Wolach is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Wolach, Ofir, et al.. (2025). Acute leukemia of ambiguous lineage: the known and the uncertain. Haematologica. 111(3). 813–827.
2.
Goldberg, Idan, Adi Shacham Abulafia, Avi Leader, et al.. (2024). Interferon Inhibits Netosis in Neutrophils Derived from Patients with Myeloproliferative Neoplasms in a Neutrophil Subpopulation-Specific Manner. Blood. 144(Supplement 1). 1762–1762. 1 indexed citations
3.
Rosenberg, Elli, et al.. (2024). Case report: VEXAS syndrome with excellent response to treatment with azacitidine. Annals of Hematology. 103(12). 5935–5939. 2 indexed citations
4.
Goldberg, Idan, Avi Leader, Galia Spectre, et al.. (2024). Interferon-α Inhibits NET Formation in Neutrophils Derived from Patients with Myeloproliferative Neoplasms in a Neutrophil Sub-Population-Specific Manner. International Journal of Molecular Sciences. 25(24). 13473–13473. 2 indexed citations
5.
Raanani, Pia, et al.. (2023). Warburg-Effect Driven Lactic Acidosis Is Associated with Early Death in Patients with Lymphoma. Blood. 142(Supplement 1). 6307–6307.
6.
Canaani, Jonathan, Daniel A. Pollyea, Marc Schwartz, et al.. (2023). Venetoclax‐based salvage therapy for adult patients with relapsed/refractory acute lymphoblastic leukemia. European Journal Of Haematology. 111(3). 365–372. 6 indexed citations
7.
Goldberg, Idan, Galit Granot, Alona Telerman, et al.. (2023). Extracorporeal photopheresis induces NETosis in neutrophils derived from patients with chronic graft‐vs‐host disease. Journal of Clinical Apheresis. 38(5). 615–621. 2 indexed citations
8.
Lahav, Meir, et al.. (2022). Identification of Cancer Cells in the Human Body by Anti-Telomerase Peptide Antibody: Towards the Isolation of Circulating Tumor Cells. International Journal of Molecular Sciences. 23(21). 12872–12872. 1 indexed citations
9.
Shimony, Shai, Moshe Yeshurun, Ofir Wolach, et al.. (2021). Post-transplantation maintenance with sorafenib or midostaurin for FLT3 positive AML patients – a multicenter retrospective observational study. Leukemia & lymphoma. 62(10). 2475–2481. 3 indexed citations
10.
11.
Telerman, Alona, Galit Granot, Moshe Yeshurun, et al.. (2021). Neutrophil Extracellular Traps Are Increased in Chronic Myeloid Leukemia and Are Differentially Affected by Tyrosine Kinase Inhibitors. Cancers. 14(1). 119–119. 17 indexed citations
12.
Pasvolsky, Oren, Liat Shargian, Uri Rozovski, et al.. (2021). Eltrombopag for enhancement of platelet engraftment in patients undergoing allogeneic cord blood transplantation. Leukemia & lymphoma. 62(11). 2747–2754. 5 indexed citations
13.
Pasvolsky, Oren, Shai Shimony, Moshe Yeshurun, et al.. (2021). Maintenance therapy after allogeneic hematopoietic transplant for acute myeloid leukemia: a systematic review and meta-analysis. Acta Oncologica. 60(10). 1335–1341. 12 indexed citations
14.
15.
Ganzel, Chezi, Ron Ram, Alexander Gural, et al.. (2020). Venetoclax is safe and efficacious in relapsed/refractory AML. Leukemia & lymphoma. 61(9). 2221–2225. 30 indexed citations
16.
Shargian, Liat, Ofir Wolach, Uri Rozovski, et al.. (2020). Sequential treatment with FLAG-IDA/treosulfan conditioning regimen for patients with active acute myeloid leukemia. Annals of Hematology. 99(12). 2939–2945. 1 indexed citations
17.
Luttwak, Efrat, David Hagin, Chava Perry, et al.. (2020). Anti-CD19 CAR-T therapy for EBV-negative posttransplantation lymphoproliferative disease—a single center case series. Bone Marrow Transplantation. 56(5). 1031–1037. 27 indexed citations
18.
Yeshurun, Moshe, Uri Rozovski, Oren Pasvolsky, et al.. (2020). Efficacy of folinic acid rescue following MTX GVHD prophylaxis: results of a double-blind, randomized, controlled study. Blood Advances. 4(16). 3822–3828. 6 indexed citations
19.
Shargian, Liat, Anat Gafter‐Gvili, Haim Ben‐Zvi, et al.. (2019). Risk factors for mortality due to Acinetobacter baumannii bacteremia in patients with hematological malignancies – a retrospective study. Leukemia & lymphoma. 60(11). 2787–2792. 13 indexed citations
20.
Elf, Shannon, Nouran S. Abdelfattah, Edwin Chen, et al.. (2016). Mutant Calreticulin Requires Both Its Mutant C-terminus and the Thrombopoietin Receptor for Oncogenic Transformation. Cancer Discovery. 6(4). 368–381. 189 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Masatsugu Tanaka Breakdown of academic impact, for papers by Lori Anderson Breakdown of academic impact, for papers by Krzysztof Kałwak Breakdown of academic impact, for papers by Odile Fenneteau Breakdown of academic impact, for papers by Kimikazu Matsumoto Breakdown of academic impact, for papers by Emmanuelle Tavernier Breakdown of academic impact, for papers by Friedrich Stölzel Breakdown of academic impact, for papers by Hsiu‐Hao Chang Breakdown of academic impact, for papers by Celalettin Üstün Breakdown of academic impact, for papers by J Treleaven
Rankless by CCL
2026